Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (KCT0011372) titled 'A clinical study to evaluate the safety and anti-cancer efficacy of administering an advanced biologic drug (AB-201) utilizing stem cells to patients with advanced breast cancer who have over-expression of the HER2 protein' on Dec. 23, 2025.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable
Primary Sponsor: Konyang University Hospital
Condition:
Neoplasms
Intervention:
Biological/Vaccine, Non-Stem Cell : 1. Study design
As a dose escalation, during the dose escalation phase of the study, up to thr...